Abivax SA
NASDAQ:ABVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Abivax SA
NASDAQ:ABVX
|
FR |
|
Oversea-Chinese Banking Corporation Ltd
F:OCBB
|
SG |
|
K
|
Kulicke and Soffa Industries Inc
XMUN:KU1
|
SG |
Intrinsic Value
The intrinsic value of 
Abivax SA (ABVX) under the Base Case is 24.85 USD per share.
Compared with the current market price of 87.49 USD, the stock appears
Overvalued by 72% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Abivax Does
Abivax is a biotechnology company that develops drug candidates for inflammatory and immune-driven diseases. Its main work is research and clinical testing, especially for conditions like ulcerative colitis, where it is trying to turn its lead molecule into a prescription medicine. It is not a broad drug seller; it is a drug developer that owns and advances its own clinical programs.
- Headquarters
- France FR
- Employees
- 80
- IPO date
- Jun 26, 2015
Earnings Waterfall
Abivax SA
The intrinsic value for Abivax SA (ABVX) under the Base Case is 24.85 USD.
Compared with the current market price of 87.49 USD, the stock appears Overvalued by 72% .